Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study

The Lancet Infectious Diseases

Volumn 18, Issue 4, 2018, Pages 410-418

  Beigel, John H ^a   Voell, Jocelyn ^b   Kumar, Parag ^c   Raviprakash, Kanakatte ^e   Wu, Hua ^f   Jiao, Jin An ^f   Sullivan, Eddie ^f   Luke, Thomas ^d   Davey, Richard T ^b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Henry Jackson Foundation for the Advancement of Military Medicine   (United States)

^e NAVAL MEDICAL RESEARCH CENTER   (United States)

^f SAB Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CREATINE KINASE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; RHEUMATOID FACTOR; SAB 301; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ABDOMINAL CRAMP; ADULT; ALBUMINURIA; ARTHRALGIA; ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; BOVINE; CLINICAL ARTICLE; COMMON COLD; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HEMATURIA; HUMAN; HYPOTENSION; IMMUNOGENICITY; IMMUNOGLOBULIN A DEFICIENCY; IMPETIGO; INDIGESTION; INTERTRIGO; LETHARGY; LOOSE FECES; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MYALGIA; NORMAL HUMAN; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEINURIA; RASH; RHINORRHEA; SHOULDER PAIN; SINGLE DRUG DOSE; SINUS CONGESTION; SORE THROAT; SUICIDE ATTEMPT; URINARY TRACT INFECTION; ADVERSE DRUG REACTION; ANIMAL; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PASSIVE IMMUNIZATION; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TRANSGENIC ANIMAL; UNITED STATES; YOUNG ADULT;

ADULT; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, VIRAL; CATTLE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HEALTHY VOLUNTEERS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NATIONAL INSTITUTES OF HEALTH (U.S.); PLACEBOS; UNITED STATES; YOUNG ADULT;

EID: 85040575647     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30002-1     Document Type: Article

References (14)

1. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/, Sept 27, 2017 (accessed Nov 27, 2017).
2. Arabi, YM, Balkhy, HH, Hayden, FG, et al. Middle East respiratory syndrome. N Engl J Med 376 (2017), 584–594.
3. Arabi, YM, Hajeer, AH, Luke, T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoVinfection, Saudi Arabia. Emerg Infect Dis 22 (2016), 1554–1561.
4. Winkler, AM, Koepsell, SA, The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Curr Opin Hematol 22 (2015), 521–526.
5. Beigel, JH, Tebas, P, Elie-Turenne, MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5 (2017), 500–511.
6. Matsushita, H, Sano, A, Wu, H, et al. Species-specific chromosome engineering greatly improves fully human polyclonal antibody production profile in cattle. PLoS One 10 (2015), e0130699–e0130730.
7. Lu, G, Hu, Y, Wang, Q, et al. Molecular basis of binding between novel human coronavirus MERS–CoV and its receptor CD26. Nature 500 (2013), 227–231.
8. Wang, L, Shi, W, Joyce, MG, et al. Evaluation of candidate vaccine approaches for MERS–CoV. Nat Commun, 6, 2015, 7712.
9. Corman, VM, Albarrak, AM, Omrani, AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 62 (2016), 477–483.
10. Coleman, CM, Liu, YV, Mu, H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32 (2014), 3169–3174.
11. Luke, T, Wu, H, Zhao, J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS–CoV in vivo. Science Transl Med, 8, 2016, 326ra21.
12. Luke, TC, Kilbane, EM, Jackson, JL, Hoffman, SL, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 145 (2006), 599–609.
13. Yeh, KM, Chiueh, TS, Siu, LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 56 (2005), 919–922.
14. Arabi, YM, Al-Omari, A, Mandourah, Y, et al. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med 45 (2017), 1683–1695.